Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.

High-grade urothelial cancer contains intrinsic molecular subtypes that exhibit differences in underlying tumor biology and can be divided into luminal-like and basal-like subtypes. We describe here the first subtype-specific murine models of bladder cancer and show that Upk3a-CreERT2; Trp53L/L; PtenL/L; Rosa26LSL-Luc (UPPL, luminal-like) and BBN (basal-like) tumors are more faithful to human bladder cancer than the widely used MB49 cells. Following engraftment into immunocompetent C57BL/6 mice, BBN tumors were more responsive to PD-1 inhibition than UPPL tumors. Responding tumors within the BBN model showed differences in immune microenvironment composition, including increased ratios of CD8+:CD4+ and memory:regulatory T cells. Finally, we predicted and confirmed immunogenicity of tumor neoantigens in each model. These UPPL and BBN models will be a valuable resource for future studies examining bladder cancer biology and immunotherapy.Significance: This work establishes human-relevant mouse models of bladder cancer. Cancer Res; 78(14); 3954-68. ©2018 AACR.

[1]  J. Terzic,et al.  The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice , 2019, Journal of Translational Medicine.

[2]  S. Agarwal,et al.  Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks , 2019, Cells.

[3]  E. Batourina,et al.  Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells , 2019, Nature Communications.

[4]  E. Sacco,et al.  The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients. , 2018, Journal of geriatric oncology.

[5]  A. Shilatifard,et al.  A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer , 2017, Oncogene.

[6]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[7]  A. Ravaud,et al.  Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[9]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[10]  C. Perou,et al.  Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. , 2016, Journal of the National Cancer Institute.

[11]  P. Sharma,et al.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.

[12]  T. Curiel,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. L. Calle,et al.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.

[14]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[15]  Lisle E. Mose,et al.  Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. , 2016, JCI insight.

[16]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[17]  Yuxin Yin,et al.  The tumor suppressor PTEN has a critical role in antiviral innate immunity , 2015, Nature Immunology.

[18]  J. McKiernan,et al.  Modelling bladder cancer in mice: opportunities and challenges , 2014, Nature Reviews Cancer.

[19]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[20]  A. Scorilas,et al.  A new tumor suppressor role for the Notch pathway in bladder cancer , 2014, Nature Medicine.

[21]  Xavier Paoletti,et al.  EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype , 2014, Science Translational Medicine.

[22]  Charles M. Perou,et al.  Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer , 2014, Clinical Cancer Research.

[23]  P. Greenberg,et al.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells , 2014, Nature Protocols.

[24]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[25]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[26]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[27]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[28]  P. Oliveira,et al.  Review: BBN as an urothelial carcinogen. , 2012, In vivo.

[29]  Mårten Fernö,et al.  A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.

[30]  Chris Albanese,et al.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.

[31]  Jens-Peter Volkmer,et al.  Three differentiation states risk-stratify bladder cancer into distinct subtypes , 2012, Proceedings of the National Academy of Sciences.

[32]  Derek Y. Chiang,et al.  MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery , 2010, Nucleic acids research.

[33]  Scott H. Randell,et al.  Basal cells as stem cells of the mouse trachea and human airway epithelium , 2009, Proceedings of the National Academy of Sciences.

[34]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[35]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[36]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[37]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[38]  E. Sandgren,et al.  Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. , 2000, The American journal of pathology.

[39]  T. Sun,et al.  Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. , 1999, Cancer research.

[40]  I. Summerhayes,et al.  Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. , 1979, Journal of the National Cancer Institute.